Fungal peritonitis in patients on peritoneal dialysis: incidence, clinical features and prognosis.
Fungal peritonitis occurred in 17 patients on chronic peritoneal dialysis. The incidence of infection per 100 patient-dialysis months was 0.36 for patients on intermittent peritoneal dialysis and 1.6 for patients on continuous ambulatory dialysis (p less than 0.005). Initial clinical findings included abdominal pain (76%), fever (59%), cloudy dialysate (76%) and poor dialysate outflow (6%). 15 patients received antibiotics within 4 weeks of developing peritonitis. All infections were caused by yeasts, with Candida parapsilosis and Candida albicans as the most common species. 14 patients were unable to continue peritoneal dialysis due to persistent or relapsing infection or the development of complications. 2 of the 3 patients who were able to continue peritoneal dialysis were treated with catheter replacement, intraperitoneal miconazole and oral ketoconazole.
D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000627:therapeutic use; D002408:Catheters, Indwelling / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D005437:Flucytosine / Q000627:therapeutic use; D006801:Humans; D007654:Ketoconazole / Q000627:therapeutic use; D008297:Male; D008825:Miconazole / Q000627:therapeutic use; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy / Q000209:etiology*; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D010538:Peritonitis / Q000188:drug therapy / Q000209:etiology*; D011379:Prognosis
D008825:Miconazole; D000666:Amphotericin B; D005437:Flucytosine; D007654:Ketoconazole